Navigation Links
MiMedx Announces 2012 Results
Date:3/7/2013

KENNESAW, Ga., March 7, 2013 /PRNewswire/ -- MiMedx Group, Inc.  (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the year ended December 31, 2012.

Highlights of 2012 Results include:

  • Tripling of Revenue over 2011
  • First full year of positive Adjusted EBITDA
  • Adjusted EBITDA increased by nearly $9 million
  • Gross Margins at record level of 81%

    • Full Year and Fourth Quarter 2012 ResultsThe Company recorded record revenue for the year ended December 31, 2012, with revenue of $27.1 million, more than three times 2011 full year revenue of $7.8 million.  Earnings before interest, taxes, depreciation, amortization, impairment of intangibles, earn-out liability and share based compensation (Adjusted EBITDA*) for the year ended December 31, 2012, were $2.4 million, a $8.7 million improvement as compared to the Adjusted EBITDA loss of $6.3 million for the year ended December 31, 2011.

    The fourth quarter of 2012 marked the 8th consecutive quarter in which the Company reported improved gross margins. The Company's 2012 gross margins of 81% are nearly a forty-two percentage point improvement over full year 2011 gross margins of 57%.

    The Company recorded record revenue for the quarter ended December 31, 2012, with revenue of $10.5 million, an increase of 299% or $7.9 million over fourth quarter of 2011 revenue of $2.6 million, and a 32% increase over the third quarter of 2012.  Adjusted EBITDA* for the quarter ended December 31, 2012, were $411,000, a $2.1 million improvement as compared to the Adjusted EBITDA loss of $1.64 million for the quarter ended December 31, 2011.

    Management Commentary on 2012 ResultsParker H. "Pete" Petit, Chairman and CEO, stated, "2012 was an excellent year by all measurements. We
    '/>"/>

    SOURCE MiMedx Group, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. MiMedx Group to Present at the 6th Annual OneMedForum
    2. MiMedx Group to Present at the Stifel Nicolaus 2012 Healthcare Conference
    3. CCS Medical Announces Agreement with LifeScan
    4. HUYA Bioscience Announces Partnership With Shanghai Zhangjiang Biotech Pharmaceutical Base
    5. AVANIR PHARMACEUTICALS ANNOUNCES RESEARCH COLLABORATION WITH DEPARTMENT OF VETERANS AFFAIRS FOR SCREENING PSEUDOBULBAR AFFECT (PBA) SYMPTOMS IN VETERANS WITH TRAUMATIC BRAIN INJURY
    6. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Impax Laboratories Inc.
    7. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
    8. DMH International Announces The Launch of TouchPACS
    9. Psyche Systems Announces Availability of Toxicology LIS
    10. Jazz Pharmaceuticals Announces Pricing Of Public Offering Of Ordinary Shares By Selling Shareholders
    11. DDS Lab Announces Strategic Alliance with United Concordia
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/21/2013)... FREDERICK, Md. , May 21, 2013 /PRNewswire/ ... inexpensive, disposable drug-free consumer electronic devices, announced that ... is presenting today to the FDA,s Medical Advisory ... reclassifying the company,s products for over the counter ... the FDA developed its medical device classification schema," ...
    (Date:5/21/2013)... , May 21, 2013  Janssen R&D Ireland ... from the global Phase 3 PROMISE study demonstrating ... (TMC435) led to sustained virologic response 12 weeks ... percent of treatment-experienced genotype 1 chronic hepatitis C ... stages of liver fibrosis, when administered once daily ...
    (Date:5/21/2013)... , May 21, 2013 ... report is available in its catalogue: ... and Reimbursement Scenario for Medical Devices in ...   Changing Regulatory ... the US Market   ...
    Breaking Medicine Technology:BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4
    ... M. Bergman, Chairman and Chief Executive Officer of ... the largest provider of health care products and ... impact of a world without effective antibiotics before ... leaders of society at the World Economic Forum,s ...
    ... 2012  Vision-Sciences, Inc. (NASDAQ:  VSCI), a leading provider ... disposable EndoSheath® technology, today announced its participation at ... TIME: 2:30 PM EST ... "register/ watch event now" button. This ...
    Cached Medicine Technology:Henry Schein's Chairman and CEO Addresses the World Economic Forum 2Henry Schein's Chairman and CEO Addresses the World Economic Forum 3Vision-Sciences, Inc. to Webcast, Live, at RetailInvestorConferences.com on February 2nd 2
    (Date:5/21/2013)... awarded New York University neuroscientist J. Anthony Movshon its ... "pioneering work on the neuroscience of vision." , ... Science, is the second NYU neuroscience professor to receive ... honor in 2011 in recognition of his "seminal studies ... learning, and fear memory." , Movshon, a faculty ...
    (Date:5/21/2013)... May 21, 2013 Representatives with Hammerhead Bicycles ... a success that the company has achieved its overall goal ... day one was to move Hammerhead Bicycles from a house ... President Scott Robertson. , Robertson explained that the bike shop ... to exclusively focus on all things 29er and 650b. ...
    (Date:5/21/2013)... Three major Ohio universities and four hospitals have ... a new collaborative research program aimed exclusively at finding ... Dimes intends to invest $10 million in the program ... Prematurity Research Center -- Ohio Collaborative is a unique ... the March of Dimes. "This new transdisciplinary, team-based research ...
    (Date:5/21/2013)... 21, 2013 Healthcare Solutions, the ... Management, today announced that it was honored to ... advisory meeting. Conferred annually, the Innovation Award ... to create cutting edge programs that improves cost ... was recognized for its clinical and IT solutions ...
    (Date:5/21/2013)... A plastic surgery Internet marketing ... surgery SEO services following an Internet survey. , ... the “Best Plastic Surgery SEO Services”. , Sources ... predictable. Well-known in the plastic surgery Internet marketing ... any other selection based on superior client results. ...
    Breaking Medicine News(10 mins):Health News:NYU's Movshon receives Lashley Award for his research on the neuroscience of vision 2Health News:Hammerhead Bicycles Now a Standalone Brand 2Health News:New multi-million dollar research center aims to solve the mystery of premature birth 2Health News:New multi-million dollar research center aims to solve the mystery of premature birth 3Health News:Healthcare Solutions Receives Innovation Award From Catamaran 2Health News:JD Media Surge's CosmeticSurgeonsOnline.com Voted #1 Source for Plastic Surgery SEO 2
    ... High vitamin D concentration in the blood is not ... report in an article published online May 27 in ... , Laboratory studies suggested that high doses of vitamin ... epidemiological studies that have examined the relationship have reported ...
    ... Genes Independently Involved in Melanoma , Mutations in ... role in melanoma, independent of the effect of the ... at a location on chromosome 9 that is frequently ... inactivation of the p16 tumor suppressor gene occurs frequently ...
    ... better overall survival , , TUESDAY, May 27 (HealthDay ... disease-free survival in women with early-stage breast cancer, ... trial included 1,246 women with early, non-metastatic breast ... with fluorouracil, epirubicin, and cyclophosphamide (FEC), or FEC ...
    ... that the brain repairs nerve damage, wherein cells known as ... are a type of support cell in the brain that ... up damaged nerves during brain injury and then form scar ... colleagues have now found that astrocytes have another trick up ...
    ... Rural Seniors in OH, TX, NC, IL, PA, TN, ... WASHINGTON, May 27 As Members of Congress,are in ... district work,period, national and long term care leaders are ... Bush Administration, and warning,that rural seniors, care needs will ...
    ... should be choice for patients with higher BMI , , ... in infection risk if a catheter for dialysis is inserted ... critically ill patients, French researchers report. , Currently, it,s widely ... than the leg catheter. , The researchers compared rates of ...
    Cached Medicine News:Health News:No association found between vitamin D concentration in blood and risk of prostate cancer 2Health News:Also in the May 27 JNCI 2Health News:Also in the May 27 JNCI 3Health News:Also in the May 27 JNCI 4Health News:Paclitaxel Plus Chemo Improves Outcomes in Early Breast Cancer 2Health News:AHCA, Alliance Warn Rural Seniors Will Bear Major Brunt of Bush Administration's Medicare Cuts 2Health News:AHCA, Alliance Warn Rural Seniors Will Bear Major Brunt of Bush Administration's Medicare Cuts 3Health News:Dialysis Catheter Placement Makes Little Difference in Infection Risk 2
    Designed to insert eye spheres using spring loaded plunger. Polished finish. Overall length: 125 mm, 4.9 inches....
    Size: Large. 24.50 mm by 26.00 mm. Clear lucite. Supplied sterile....
    ... x 80 mm. Storz offers the ... by Harvey A. Lincoff, M.D. ... sponge which is non-toxic and non-antigenic. ... to minimize scleral intrusion. These implants ...
    ... 5.0 x 80 mm. Storz offers ... designed by Harvey A. Lincoff, M.D. ... sponge which is non-toxic and non-antigenic. ... to minimize scleral intrusion. These implants ...
    Medicine Products: